Certara, a company that accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development, completed the acquisition of Applied BioMath, a company providing model-informed drug discovery and development support to help accelerate and de-risk therapeutic research and development. Financial terms were not disclosed. “Together, Applied BioMath and Certara have the scientific and computational expertise to industrialize QSP biosimulation methods. Our respective QSP businesses are complementary with regards to clients, geographic location, indications and expertise. Additionally, Certara’s existing biosimulation and AI portfolios serve as accelerators for the combined team making QSP more widely available and accessible across the industry,” William F Feehery, Certara CEO.